BioStem Techn.

BioStem Technologies has shifted its strategic focus from clinic wound care to surgical biologics for hospitals through the acquisition of BioTissue, and is building a direct sales platform with GPO contracts and an expanded sales team. In Q2 2026 the company reported $7.9m in revenue, an adjusted EBITDA loss of $4.6m and $7m in cash; the full-year guidance was raised to $26–29m. A planned technology transfer in H1 2027 is expected to improve gross margin by 15–20 percentage points and move profitability toward break-even. BioStem is preparing the market launch of Catalyze (510(k)) for end-2026 and is seeking non-dilutive financing options to strengthen the balance sheet. » Mere på de.investing.com

At the Micro-Cap Conference, BioStem Technologies announced a transition from a wound‑care‑centered model to a regenerative medicine platform focused on hospitals and surgical applications. The company is shifting 87% of revenue to procedure‑based DRG reimbursements, expanding its sales team and GPO contracts, and raising its 2026 revenue guidance to $26–29 million. Q2 revenue rose sequentially to $7.9 million but remained lower year‑over‑year; gross margin and cash balance declined. A technology transfer planned for H1 2027 is intended to improve margins. BioStem is building clinical evidence in urology, foot/ankle surgery and orthopedics and plans vertical integration and geographic expansion. » Mere på de.investing.com

BioStem reported Q4 2025 EPS of -$0.39 (forecast $0.02) and revenue of $10.1 million versus expected $55.2 million, after which the stock fell 6.74% to $5.49. The revenue decline is attributed to changed Medicare reimbursement policies and weaker physician-practice business; operating expenses rose due to large allowances for doubtful accounts. The company reports an improved gross margin of 97%, points to the acquisition of BioTissue and plans for product launches and an FDA approval in 2026, but still expects continued cash outflows. » Mere på de.investing.com